J&J Continues Momentum In Second Quarter

Johnson & Johnson’s medical device sales were up nearly 60% year-over-year in the second quarter of 2021 while Abbott reported 51% growth in its device business, reflecting the recovery in procedure volumes since the worst days of the pandemic in mid-2020.

Earning Report Q2

Procedure volumes for most of Johnson & Johnson’s device businesses returned to their pre-pandemic levels in the second quarter of 2021. However, a few markets, including orthopedic implants and vision surgery, are still showing some impact of COVID-19.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Robotic Surgery

More from Surgery